Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of ZX-7101A Suspension vs Tablets in Healthy Chinese Males
NCT06841926Phase 1Completed
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Seloxavir marboxil in influenza (2 arms), sponsored by Zenshine Pharmaceuticals Co., Ltd. Primary endpoints: Maximum Plasma Concentration (Cmax) of ZX-7101 at Day 36, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Time (AUC0-t) of ZX-7101 at Day 36 and 2 more. Started Feb 2025; status: completed.
02
Drugs
Seloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06841926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841926.